The core program in immunology was originally designed to function as an intellectual and technical resource for investigators wishing to study immunologic aspects of AIDS-related issues. This required the recruitment of scientists to this endeavor, and the development of central wet laboratory and flow cytometry facilities capable both of handling virus-infected material and of providing the unique resources and reagents necessary for AIDS-related research. These goals have largely been accomplished as a result of constructing a centralized CFAR immunology laboratory equipped for cellular and molecular studies adjacent to the CFAR BL-3 laboratory, equipping a flow cytometry laboratory with a closed flow system capable of studying viable HIV-or SIV-infected cells, and identifying group of core investigators committed to establishing an AIDS immunology program. The centralized CFAR laboratory, now populated with experienced investigators and technicians, has been at the forefront of the development of methods and reagents for the analysis of cellular immunity to HIV and SIV. The lab is equipped with: culture hoods and incubators necessary for culturing virus-infected cells; HPLC apparatus for purification of proteins, peptides and oligonucleotides; PCR equipment for identifying or isolating DNA or RNA; high-speed centrifuges for isolating viral particles or genetic material; power supplies, gel boxes and darkroom for molecular studies; and beta and gamma-counters for lymphoproliferative and cytotoxic assays. This equipment, and the reagents generated by core investigators such as purified viral proteins, recombinant vaccinia and retrovirus shuttle vectors, and monoclonal antibodies, are available to center scientists for individual use or collaborative studies. The AIDS flow cytometry facility contains a cell sorter and two cell analyzers, and is available on a priority basis for CFAR investigators. Since this is only facility at our institution that can handle viable HIV-infected cells, it is widely used for AIDS-related studies by investigators from many disciplines. The planned focus of the immunology core in future years is to provide: (a) technical assistance, training and reagents necessary for the analysis of immune responses to HIV and SIV and (b) technical assistance, reagents and the equipment necessary for sophisticated flow cytometric analysis and isolation of virus-infected and uninfected cells. Such efforts are expected, as in the past, to continue to promote interdisciplinary collaborations, particularly with participants in the Clinical Research, Clinical Retrovirology and Molecular Retrovirology CFAR cores.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-10
Application #
2844579
Study Section
Project Start
Project End
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
10
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Fredericksen, Rob J; Mayer, Kenneth H; Gibbons, Laura E et al. (2018) Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary Care. J Gen Intern Med 33:1661-1668
Wilson, Kate S; Wanje, George; Masese, Linnet et al. (2018) A Prospective Cohort Study of Fertility Desire, Unprotected Sex, and Detectable Viral Load in HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 78:276-282
Ikoma, Minako; Gantt, Soren; Casper, Corey et al. (2018) KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite. PLoS One 13:e0192659
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Gómez, Laurén A; Crowell, Claudia S; Njuguna, Irene et al. (2018) Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 37:916-922
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Njuguna, Irene N; Wagner, Anjuli D; Omondi, Vincent O et al. (2018) Financial Incentives for Pediatric HIV Testing in Kenya. Pediatr Infect Dis J 37:1142-1144

Showing the most recent 10 out of 1275 publications